Image de couverture de livre

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Danilo De Novellis, Raffaele Fontana, Bianca Serio, Emilia Vaccaro, Roberto Guariglia, Denise Morini, Michela Rizzo, Valentina Giudice, Carmine Selleri
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Cancer Medicine
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Mechanisms of resistance to daratumumab in patients with multiple myeloma
par: Katrine Fladeland Iversen
Publié: (2024)

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
par: Danai Dima, et autres
Publié: (2024)

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation
par: Yutaka Shimazu, et autres
Publié: (2024)

Electrophysiological Studies in Combination With Interim‐Positron Emission Tomography Scan for Prevention of Severe Brentuximab‐Vedotin‐Induced Neurotoxicity
par: Luca Pezzullo, et autres
Publié: (2025)

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma
par: Xi‐xi Yin, et autres
Publié: (2024)

Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
par: Luca Bettolini, et autres
Publié: (2024)

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
par: Taku Kikuchi, et autres
Publié: (2024)

Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN
par: Rebecca Silbermann, et autres
Publié: (2024)

Anti‐ CD38 VHH antibody ( JK36 ) reliably detects CD38 yet uncovers CD38 downregulation in a subset of daratumumab‐treated multiple myeloma patients
par: Veronika Ecker, et autres
Publié: (2025)

Exact and Heuristic Solution Approaches for the Cluster Deletion Problem on General Graphs
par: Giuseppe Ambrosio, et autres
Publié: (2025)

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
par: Xiaoyan Han, et autres
Publié: (2024)

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study
par: Maria Carmen Martorelli, et autres
Publié: (2025)

Ideología, verdad y legitimación / Osvaldo Guariglia
par: Guariglia, Osvaldo

Democracia y justicia global: obstáculos y perspectivas
par: Osvaldo Guariglia
Publié: (2012)

Chapter Farmaci, farmacisti e farmacie a Firenze
par: Selleri, Silvia
Publié: (2024)

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
par: Syed Naqvi, et autres
Publié: (2024)

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
par: M. R. Seefat, et autres
Publié: (2025)

Spatial working memory in Alzheimer’s disease. A study using the Corsi block-tapping test
par: Carla Cristina Guariglia
Publié: (2007)

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
par: Danilo De Novellis, et autres
Publié: (2024)

Identifying Kronecker product factorizations
par: Voet, Yannis, et autres
Publié: (2025)

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
par: Sueh‐li Lim, et autres
Publié: (2025)

Correction to “Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival”
Publié: (2024)

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma
par: Alexandrina Balanean, et autres
Publié: (2024)

Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
par: Deniz Gezer, et autres
Publié: (2024)

MRD ‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥ VGPR / MRD ‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM
par: Alessandro Gozzetti, et autres
Publié: (2026)

Diagnóstico pouco frequente de dor abdominal em unidade de emergência infantil
par: Suelen Bianca S. Martins
Publié: (2010)

The role of migration traps in the formation of binary black holes in AGN disks
par: Vaccaro, Maria Paola, et autres
Publié: (2025)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
par: Benjamin A. Derman, et autres
Publié: (2025)

Does Politics Influence Environmental, Social, and Governance Disclosure? Empirical Evidence From US Listed Firms
par: Gianluca Moretti, et autres
Publié: (2025)

Dysplastic plasma cells in multiple myeloma
par: Marco P. Barros Pinto
Publié: (2025)

New standard of care for multiple myeloma?
par: Mary Beth Nierengarten
Publié: (2024)

Accelerated approval of multiple myeloma therapies
par: Mary Beth Nierengarten
Publié: (2024)

Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
par: Jahanzaib Khwaja, et autres
Publié: (2025)

Medidas de proteção contra COVID-19 sob ótica dos profissionais de saúde: Estudo transversal e analítico
par: Bianca Fontana Aguiar
Publié: (2023)

Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
par: Othman Salim Akhtar, et autres
Publié: (2024)

A Bayesian joint model of multiple longitudinal and categorical outcomes with application to multiple myeloma using permutation-based variable importance
par: Alvares, Danilo, et autres
Publié: (2024)

Navigating the evolving management of smoldering multiple myeloma
par: M. Bakri Hammami, et autres
Publié: (2026)

Dynamic risk prediction model for multiple myeloma
par: Mary Beth Nierengarten
Publié: (2024)

Are we there yet? CAR ‐T therapy in multiple myeloma
par: Eitan Mirvis, et autres
Publié: (2024)

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities
par: Subhasree Kumar, et autres
Publié: (2025)